Tuesday, December 11, 2018 11:33:58 AM
I'm guessing we'll see this rise up to .50+
TEL AVIV, Israel and BETHESDA, Maryland, Dec. 11, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has started the accreditation process in accordance with ISO 15189:2012 for its drug screening and diagnostics laboratory, which it expects to receive by the end of next year. ISO is the accepted "International Organization for Standardization", and ISO 15189:2012 is the international standard for quality management and competence for Medical Laboratories by regulators and accrediting bodies. This accreditation demonstrates to the marketplace and to regulators that the medical laboratory has met the highest scientific standards for accreditation and compliance.
Through its 100% owned subsidiary, G.R.I.N ULTRA, Israel, Cannabics Pharmaceuticals will leverage its state-of-the-art high throughput screening platform utilizing cannabis extracts on human cancer cells and recommend the optimal cannabinoid treatment for each patient based on their own biopsies and personalized clinical data.
Eyal Ballan, Co-founder and chief Scientist of Cannabics said, "Cannabics is committed to developing novel cannabinoid-based drugs and providing the highest quality diagnostic services for cancer patients. We are focused on whole plant extraction, distinguishing between variations in cannabinoid profiles, supporting decision making in cancer treatment which can provide physicians, caregivers and patients a whole new layer of data that was unavailable to them previously, as well as help provide valuable insight which will reflect on their medical cannabis treatment regime."
The accreditation will allow Cannabics to commercialize its diagnostics and allow the analysis of patients' biopsies in our new laboratory, in which drug sensitivity tests will deliver a personalized data report which may be used for more specified treatment decisions.
Recent CNBX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/15/2024 02:58:24 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:27:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 03:13:35 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM